Stringent Datalytics’ Post

From MassDevice: Johnson & Johnson acquisition of Shockwave Medical for approximately $13.1 billion marks a significant shift in the landscape of #surgicalrobotics and medical technology. By integrating Shockwave's intravascular lithotripsy (IVL) technology, known for its innovative approach to treating calcified arterial plaque, Johnson & Johnson significantly bolsters its #MedTech portfolio, particularly in #cardiovascular intervention. This move not only highlights the growing importance of advanced catheter-based treatments in managing coronary and #peripheralarterydisease but also underscores the industry's trend towards consolidating high-growth market segments in cardiovascular care. #MedicalDevices #RoboticSurgery #SurgicalRobot #HealthTechInnovation #Aquisition

Interesting thoughts from CX symposium!

💞 Field Medical starts FIH study for FieldForce Ablation System The FieldForce Ablation System is said to be the first and only contact force pulsed field ablation (PFA) system for the time-efficient treatment of people with ventricular arrhythmias. The Ventricular Catheter Ablation Study (VCAS) will assess the FieldForce system at Na Homolce Hospital in Prague, Czech Republic. VCAS will recruit up to 60 patients at up to five sites worldwide. The system’s potential will be assessed to address the limitations of existing PFA and radiofrequency (RF) ablation systems. It will be conducted in two parts where the VCAS-1 group concentrates on patients afflicted with ventricular tachycardia (VT). On the other hand, the VCAS-2 group is aimed at those encountering frequent premature ventricular complexes (PVCs). The trial seeks to establish that PFA can safely manage and enhance overall outcomes for patients with complex ventricular arrhythmias. Field Medical CEO Steven Mickelsen said: “Our vision at Field Medical is to transform VT ablation into a widely available, one-hour outpatient procedure with improved safety outcomes. “With the promising early data for our VCAS study, in much the same way that PFA transformed AF, the FieldForce Ablation System is optimised to transform how ventricular arrhythmias are treated, offering hope to millions of patients worldwide. “With the strong investor support, renown physician engagement and the groundbreaking potential of our technology, we are set to redefine the standards of cardiac ablation once again.” Read more online: https://lnkd.in/gKCk7rgK 📰 Follow Medical Device Developments to receive the latest medical device news daily and to subscribe to our weekly newsletter #MedicalDeviceDevelopments #medicaldevices #medicalmanufacturing

𝐂𝐞𝐧𝐭𝐫𝐢𝐟𝐮𝐠𝐚𝐥 𝐁𝐥𝐨𝐨𝐝 𝐏𝐮𝐦𝐩 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐩𝐨𝐫𝐭: 𝐀𝐝𝐯𝐚𝐧𝐜𝐞𝐦𝐞𝐧𝐭𝐬 𝐢𝐧 𝐂𝐚𝐫𝐝𝐢𝐚𝐜 𝐒𝐮𝐫𝐠𝐞𝐫𝐲 𝐚𝐧𝐝 𝐋𝐢𝐟𝐞-𝐒𝐚𝐯𝐢𝐧𝐠 𝐃𝐞𝐯𝐢𝐜𝐞𝐬 𝐂𝐥𝐢𝐜𝐤 𝐇𝐞𝐫𝐞, 𝐓𝐨 𝐆𝐞𝐭 𝐅𝐫𝐞𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 https://lnkd.in/gPMz_gq5 Market Overview: The centrifugal blood pump market is growing rapidly due to the increasing demand for advanced cardiac assist devices and improved outcomes in heart surgeries. Centrifugal blood pumps are critical in providing temporary circulatory support during surgeries, particularly for patients with heart failure or those undergoing open-heart procedures. These pumps ensure controlled blood flow while minimizing damage to blood cells, making them essential in extracorporeal membrane oxygenation (ECMO) and cardiopulmonary bypass (CPB) systems. Technological innovations and the rising prevalence of cardiovascular diseases are key drivers in this market's expansion. Market Trends: Rising Prevalence of Cardiovascular Diseases: As heart disease remains a leading cause of mortality worldwide, the demand for advanced cardiac assist devices, including centrifugal blood pumps, continues to rise. Technological Advancements in Blood Pump Design: Innovations in centrifugal pump technology, such as improved biomaterials and automated systems, are enhancing performance, reducing hemolysis, and improving patient outcomes during cardiac surgeries. Increasing Use in ECMO and CPB Procedures: The growing use of centrifugal pumps in extracorporeal membrane oxygenation (ECMO) for critical care patients and cardiopulmonary bypass (CPB) during surgeries is driving market demand. Focus on Minimizing Blood Trauma: Manufacturers are focusing on developing pumps that minimize blood trauma and improve patient safety, particularly in long-term cardiac support and complex surgical procedures. Growing Adoption in Emerging Markets: As healthcare infrastructure improves in emerging economies, the adoption of advanced medical devices, including centrifugal blood pumps, is on the rise, contributing to market growth. #Company Medtronic Thoratec Corporation Terumo Medical Corporation QURA Srl Braile Biomédica Getinge #Type Electronic Mechanical #Applications Hospitals Ambulatory Surgical Centers Specialty Clinics Other #CentrifugalBloodPump #CardiacSurgery #HeartFailure #CardiovascularHealth #ECMO #CardiopulmonaryBypass #HealthcareInnovation #MedicalDevices #PatientCare #CardiacAssistDevices #HealthcareTechnology #CardiovascularDisease #SurgicalInnovation

Advancing Lung Nodule Treatment: An Innovation with the Contact Laser System 1. Patient Profile and Medical Background: In a momentous medical intervention, we present the case of a 35-year-old patient who sought medical consultation due to a nodule located in the lateral segment of the middle lobe of their right lung. Initially detected during a routine physical examination three months earlier, the nodule measured approximately 8 x 6mm. The patient's medical history revealed a notable instance of hyperthyroidism, effectively managed with long-term methimazole and propranolol therapy, alongside a history of smoking. 2. Utilization of State-of-the-Art Technology: MedexMedical's Contact Laser System. During this pioneering procedure, the medical institution leveraged advanced technology provided by MedexMedical, formerly marketed by Photomedex Surgical, an American enterprise. Specifically, the procedure employed the LaserPro980® model coupled with a CEF 0.6-SMA, a flexible endoscopic fiber tailored for tissue ablation. This sophisticated system facilitated precise and targeted treatment of the lung nodule, demonstrating the potential of advanced laser technology in modern medical interventions. 3. Precision Ablation and Promising Outcomes: The percutaneous ablation of the small nodule was conducted with meticulous precision, commencing with an initial power setting of 3.5W and an ablation duration of 360 seconds. The strategic approach to ablating the nodule yielded outstanding results, underscoring the effectiveness of the LaserPro980® and its diverse fiber delivery systems in addressing such interventions. This pioneering methodology represents a significant breakthrough in lung nodule treatment, offering optimism for patients with similar pathologies. As we progress in exploring innovative treatment modalities, the integration of laser technology offers promising avenues for minimally invasive interventions with heightened precision and favorable outcomes. #MedexMedical #MedicalInnovation #LungHealth

Last week ICU Medical Technologies obtained the patent for KronoSafe® in the USA. With this milestone, the expansion of protection internationally by choosing strategic commercialization countries continues. This recognition is added to the patents already granted (Spain and Russia) and also, the extension process continues favorable in other countries such as India, China, Canada, Australia and the rest of Europe. USA is an interesting market for a medical device like KronoSafe®, designed to increase the safety and effectiveness of temporary cardiac pacing. In 2022, the turnover of cardiovascular devices in the USA was USD 28.6 billion and with expectations of future growth (CAGR; 7.9%). KronoSafe® not only provides benefits in the field of Temporary Cardiac Stimulation directly, which in the United States represents an annual turnover of €202M (CPT Code 33210-1 / $8,103); but also in patients undergoing Transcatheter Aortic Valve Replacement (#TAVR), where favorable clinical results have been confirmed with this device. This market, with an annual turnover in the USA of $3.2B (CPT code 33361-66 / $45,000) will be an interesting Early Adopter. Reducing complications with a high economic impact, reducing costs in hospital stays and avoiding overuse of permanent pacemakers will be an interesting solution for both hospitals and insurers. #cardiology #pacemaker #cardiacstimulation #icu, #medicaldevice

Endoscopy capacity is a challenge accross the U.K.. Here is a great piece of work demonstrating the clinical, operational and financial benefits of changing patient pathways. It’s great to also see that patient comfort and satisfaction was also improved. It’s intiatives like this that really deliver value. Well done Royal United Hospitals Bath NHS Foundation Trust #patientexperience #valuebasedhealthcare #pathwaytransformation #endoscopy #tne #olympus

Our latest #ValueBasedProcurement case study has just been published. Dr Ben Colleypriest (Consultant Gastroenterologist) and Nuno Aguiar (Specialty Manager, Gastroenterology and Radiology) at Royal United Hospitals Bath NHS Foundation Trust explain how a Value Based Procurement pilot project in endoscopy delivered significant benefits for patients and reduced operating time. Read more and watch this short video ⬇️ https://lnkd.in/eKxKBuaN #VBP #NHS #TNE #TransnasalEndoscopy

Canary Completes First-in-Human Trial of Cardiac Auscultation Monitoring Sensor Canary Medical Inc. focused on the development and commercialization of its patented implantable sensor technology and complementary data and analytics ecosystem, today announced the completion of the first-in-human limited feasibility trial of their Cardiac Auscultation (Acoustic) monitoring sensor device. The device is being developed as a first-in-class implantable sensor to provide daily adjunctive objective cardiac parameter measurements enabling patients and clinicians to better manage their congestive heart failure symptoms with current medication management tools. This trial, conducted in Paraguay, represents the first successful human implantation of a cardiac auscultation sensor device. The U.S. heart failure market is projected to be $70B annually by 2030. One in five people will develop heart failure in their lifetime with half of patients dying within five years of their diagnosis. #heartfailure #heartdisease https://lnkd.in/eG8v8hMe